GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Current Ratio

IGC Pharma (IGC Pharma) Current Ratio

: 1.85 (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IGC Pharma's current ratio for the quarter that ended in Dec. 2023 was 1.85.

IGC Pharma has a current ratio of 1.85. It generally indicates good short-term financial strength.

The historical rank and industry rank for IGC Pharma's Current Ratio or its related term are showing as below:

IGC' s Current Ratio Range Over the Past 10 Years
Min: 1.02   Med: 3.19   Max: 52.73
Current: 1.85

During the past 13 years, IGC Pharma's highest Current Ratio was 52.73. The lowest was 1.02. And the median was 3.19.

IGC's Current Ratio is ranked worse than
69.84% of 1555 companies
in the Biotechnology industry
Industry Median: 3.8 vs IGC: 1.85

IGC Pharma Current Ratio Historical Data

The historical data trend for IGC Pharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.44 9.12 9.93 6.19 3.41

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.90 3.41 2.38 2.90 1.85

Competitive Comparison

For the Biotechnology subindustry, IGC Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, IGC Pharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Current Ratio falls into.



IGC Pharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

IGC Pharma's Current Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Current Ratio (A: Mar. 2023 )=Total Current Assets (A: Mar. 2023 )/Total Current Liabilities (A: Mar. 2023 )
=6.466/1.898
=3.41

IGC Pharma's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=3.583/1.936
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IGC Pharma  (AMEX:IGC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


IGC Pharma Current Ratio Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (IGC Pharma) Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma (IGC Pharma) Headlines

From GuruFocus